arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Evommune, Inc.

EVMN

$14.14 ▲ +0.72 (+5.37%) at close

9 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Evommune, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $476.1M

Dividend Yield —

Revenue Growth —

Op. Margin None

ROIC -6.2% ↗

FCF / Share $-0.82

Trailing P/E —

Price / Book 1.7x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-21.67M

↓ -48.9% —

FCF / Share Free cash flow per share

$-0.82

↑ +94.7% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
EPS Growth YoY (%)	93.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	22.9% Good Good Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	-48.9% Weak ↓ Weak Declining Year-over-year change in net income	-36.4% Weak Weak Year-over-year change in net income	21.6% Good Good Year-over-year change in net income	—	—	—	—	—	—
FCF Growth YoY (%)	94.7% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—

💰 Are margins durable? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Operating Margin (%) (%)	—	—	-133.3% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-989%)	—	—	—	—	—	—
Profit Margin (%) (%)	—	—	-124.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1140%)	—	-485.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-4144%)	—	—	—	—
FCF / Net Income (x)	1.27x Good Good Free cash flow relative to reported net income Optimal: > 1x	0.59x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	1.64x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Return on Invested Capital (%)	-6.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-11.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	5.7% Caution ↓ Caution Declining Return earned on debt + equity capital invested Optimal: > 10%	—	7.5% Fair ↓ Fair Declining Return earned on debt + equity capital invested Optimal: > 10%	11.8% Good Good Return earned on debt + equity capital invested Optimal: > 10%	10.6% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-7.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-13.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-15.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-28.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—
Return on Common Equity (%) (%)	-7.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-147%)	-13.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-192%)	6.8% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-55%)	—	9.2% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-39%)	14.4% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: At sector avg	13.0% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-13%)	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Interest Coverage (x)	-5988.50x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	-3758.00x Weak Weak Operating income divided by interest expense Optimal: > 5x	-3575.67x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—
Net Debt (USD)	$-48.32M	$-44.06M	$-26.82M	—	$-5.70M	$-16.25M	$-18.15M	—	—

📊 What does each share earn? 6 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Revenue per Share (USD)	$0.00	—	$6.47	—	$1.95	—	—	—	—
Basic EPS, GAAP (USD)	$-0.64	$15.14	$-8.07	—	$-9.48	$-14.60	$-10.47	—	—
Free Cash Flow per Share (USD)	$-0.82	—	—	—	$-15.57	—	—	—	—
Book Value per Share (USD)	$8.46	$6.52	$-117.78	—	$-103.09	$-92.97	$-80.57	—	—
Tangible Book Value per Share (USD)	$8.46	$6.52	$-117.78	—	$-103.09	$-92.97	$-80.57	—	—
Basic Weighted Avg Shares (shares)	33.67M	—	1.55M	—	1.53M	—	1.52M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Working Capital (USD)	$205.25M	$135.57M	$71.53M	—	—	$46.01M	—	—	—
Total Equity (USD)	$304.56M	$205.57M	$-183.14M	$-171.23M	$-158.24M	$-144.24M	$-122.53M	$-107.03M	$-77.71M

📋 What is driving earnings? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$0.00	$10.00M	—	$3.00M	$0.00	—	—	—
Depreciation Expense (USD)	$100.00K	—	—	—	$200.00K	—	—	—	—
Net Income, GAAP (USD)	$-21.67M	$-28.27M	$-12.47M	—	$-14.56M	$-20.73M	$-15.92M	—	—
Operating Cash Flow (USD)	$-27.50M	$-16.70M	—	—	$-23.90M	$-18.51M	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 3 years · 9 quarters

Evommune, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare EVMN with peers